홈ONC • NASDAQ
add
베이진
뉴스
재무
손익계산서
수익
순이익
| (USD) | 2025년 3월info | 전년대비 변동 |
|---|---|---|
수익 | 11.17억 | 48.64% |
운영비 | 9.41억 | 5.98% |
순이익 | 127.00만 | 100.51% |
순이익률 | 0.11 | 100.33% |
주당 수익 | 0.01 | 100.41% |
EBITDA | 4273.30만 | 118.01% |
유효 세율 | 93.92% | — |
대차대조표
총자산
총부채
| (USD) | 2025년 3월info | 전년대비 변동 |
|---|---|---|
현금 및 단기 투자 | 25.16억 | -9.91% |
총자산 | 58.42억 | 3.07% |
총부채 | 23.42억 | 1.50% |
총자기자본 | 35.00억 | — |
발행 주식 | 1.08억 | — |
주가순자산비율 | 7.93 | — |
총자산이익률 | 0.47% | — |
자본이익률 | 0.62% | — |
현금 흐름
순현금흐름
| (USD) | 2025년 3월info | 전년대비 변동 |
|---|---|---|
순이익 | 127.00만 | 100.51% |
영업 현금 흐름 | 4408.20만 | 114.29% |
투자 현금 흐름 | -1.22억 | 41.89% |
자금 조달 현금 흐름 | -3377.70만 | -120.81% |
순현금흐름 | -1.08억 | 71.43% |
잉여 현금 흐름 | -1.45억 | 62.90% |
정보
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
설립
2010. 10. 28.
직원 수
11,000
